Source-grounded facts extracted from Evommune, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Evommune, Inc. shareholders approved Ratification of Selection of Independent Registered Public Accounting Firm at the 2026-06-02 meeting.
“Proposal 2 – Ratification of Selection of Independent Registered Public Accounting Firm The proposal to ratify the selection of BDO USA, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was approved based upon the following votes: For Against Abstain Broker Non-Votes 24,664,299 430 29,765 —”
Evommune, Inc. shareholders approved Election of Directors at the 2026-06-02 meeting.
“Proposal 1 – Election of Directors The following nominees were elected to the Company’s Board of Directors to hold office until the Company's 2029 Annual Meeting of Stockholders or until their respective successors are duly elected and qualified, or until their earlier death, resignation or removal. The votes cast at the Annual Meeting were as follows: Nominee For Withheld Broker Non-Votes Luis Peña 21,859,596 1,949,148 885,750 Eugene Bauer, M.D. 23,637,920 170,824 885,750”
Evommune, Inc. reported first quarter ended March 31, 2026 results: revenue zero.
“Revenue was zero for the first quarter ended March 31, 2026, compared to $3.0 million for the same period in 2025, attributable to the Company’s strategic collaboration with Maruho related to licensing EVO756 in Japan.”
Evommune, Inc. entered into Registration Rights Agreement with certain investors (effective 2026-02-12).
“In connection with the Private Placement, the Company also entered into a Registration Rights Agreement, dated February 12, 2026 (the “Registration Rights Agreement”), with the Investors.”
Evommune, Inc. entered into Securities Purchase Agreement with certain investors valued at approximately $125 million (effective 2026-02-12).
“On February 12, 2026, Evommune, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain investors (the “Investors”) pursuant to which the Company, in a private placement (the “Private Placement”), agreed to issue and sell to the Investors an aggregate of 4,494,279 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”). Each Share was offered and sold at a purchase price of $27.88 before deducting underwriting discounts and commissions. The Private Placement is expected to close on or about February 17, 2026, subject to the satisfaction of customary closing conditions. The Company estimates that the gross proceeds to the Company from the Private Placement will be approximately $125 million, before deducting any transaction-related expenses.”
Evommune, Inc.: Amended and restated bylaws adopted in connection with IPO (effective 2025-11-07).
“Effective as of November 7, 2025, the Company adopted amended and restated bylaws (the “Restated Bylaws”) in connection with the closing of the IPO.”
Evommune, Inc.: Amended and restated certificate of incorporation filed in connection with IPO (effective 2025-11-07).
“the Company filed an amended and restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware. The Company’s board of directors (the “Board”) and stockholders previously approved the Restated Certificate to be effective as of immediately prior to the closing of the IPO.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.